Form 4: Black Diamond Therapeutics Executive Receives Stock Options and Restricted Stock Units

Brent Hatzis-Schoch, Chief Operating Officer and General Counsel of Black Diamond Therapeutics, received stock options and restricted stock units (RSUs) as part of the company's 2020 Stock Option and Incentive Plan.

Summary

• Brent Hatzis-Schoch, an officer at Black Diamond Therapeutics, received 75,000 Restricted Stock Units (RSUs) and options to purchase 175,000 shares of common stock on January 30, 2025.
• The RSUs vest in two tranches: 50% on January 30, 2026, and the remaining 50% on January 30, 2027, contingent upon continued service.
• The stock options have an exercise price of $2.52 per share.
• 25% of the stock options vest on January 30, 2026, with the remaining options vesting in 36 equal monthly installments thereafter, also contingent upon continued service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests confidence in the executive's continued contribution.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company's success.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued service and contribution from the executive.

Industry Context

Granting stock options and RSUs is a common practice in the biotechnology industry to attract, retain, and incentivize key executives. These grants align management's interests with those of shareholders, encouraging long-term value creation.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation components for executives in biotech companies like Black Diamond Therapeutics.
• Comparable companies such as Relay Therapeutics, Blueprint Medicines, and Revolution Medicines also utilize equity-based compensation to incentivize their leadership teams.
• The vesting schedules (25% after one year, then monthly) are typical for stock options in the biotech industry, promoting long-term commitment.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with long-term value creation.
• Employees may see the grants as a sign of the company's commitment to its leadership team.
• The grants have no immediate impact on customers, suppliers, or creditors.

Key Dates